The Covid antiviral pill can cut the risk of hospitalisation in half.

Spread the love

Molnupiravir is the first oral antiviral treatment for Covid to report clinical trial results. Photo: Merck

An experimental treatment for severe According to preliminary clinical trial results, Covid reduces the risk of hospitalisation or death by about half.

Molnupiravir, a tablet, was given twice a day to patients who had recently been diagnosed with the disease.

Merck, a pharmaceutical company based in the United States, stated that its results were so promising that outside monitors requested that the trial be terminated early.

It stated that it would apply for an emergency use authorisation for the drug in the United States within the next two weeks.

Dr Anthony Fauci, chief medical adviser to US President Joe Biden, called the findings “very good news,” but advised caution until the data was reviewed by the US Food and Drug Administration (FDA).

First oral treatment

If authorised by regulators, molnupiravir would be the first oral antiviral medication for Covid-19.

The pill, which was originally developed to treat influenza, is designed to introduce errors into the genetic code of the virus, preventing it from spreading in the body.

An analysis of 775 patients in the study found:

* 7.3 percent of those given molnupiravir were hospitalised

* that compares with 14.1 percent of patients who were given a placebo or dummy pill

* there were no deaths in the molnupiravir group, but eight patients who were given a placebo in the trial later died of Covid

READ ALSO:  Asia-Pacific trade deal to add 'certainty for New Zealand exporters' - minster

The data was published in a press release and has not yet been peer-reviewed.

Unlike most Covid vaccines, which target the spike protein on the outside of the virus, the treatment works by targeting an enzyme the virus uses to make copies of itself.

Merck, known by the name MSD in the UK, said that should make it equally effective against new variants of the virus as it evolves in the future.

Daria Hazuda, Merck’s vice-president of infectious disease discovery, told the BBC: “An antiviral treatment for people who are not vaccinated, or who are less responsive to immunity from vaccines, is a very important tool in helping to end this pandemic.”

Trial results suggest molnupiravir needs to be taken early after symptoms develop to have an effect. An earlier study in patients who had already been hospitalised with severe Covid was halted after disappointing results.

Global approval

Merck is the first company to report trial results of a pill to treat Covid, but other companies are working on similar treatments. Its US rival Pfizer has recently started late-stage trials of two different antiviral tablets, while Swiss company Roche is working on a similar medication.

Merck has said it expects to produce 10 million courses of molnupiravir by the end of 2021. The US government has already agreed to buy $1.2bn (£885m) worth of the drug if it receives approval from the regulatory body, the FDA.

READ ALSO:  Mnuchin reports movement on COVID-19 relief as House heads toward vote

The company said it is in ongoing discussion with other countries, including the UK, and has also agreed licensing deals with a number of generic manufacturers to supply the treatment to low and middle-income countries.

Prof Penny Ward, from King’s College London, who was not involved in the trial, said: “It is greatly hoped that the antiviral task force has, like the vaccines taskforce, pre-ordered courses of this medication.

“[This is] so that the UK can, at last, properly manage this condition by treating vaccine breakthrough disease, and relieve pressure on the NHS during the forthcoming winter.”

Prof Peter Horby, an expert in infectious diseases at University of Oxford, said: “A safe, affordable, and effective oral antiviral would be a huge advance in the fight against Covid.

“Molnupiravir has looked promising in the lab, but the real test was whether it shows benefit in patients. Many drugs fail at this point, so these interim results are very encouraging.”



Leave a Reply